Page 13 - Biocon

After run-up, Biocon stock may catch its breath

Immense long-term potential; but caution sets in as potential regulatory hurdles loom

Biocon profit at Rs 147 cr, revenue up 21%

Expansion of our biologics footprint in emerging markets and licensing agreements boosted the revenue further, says Kiran Mazumdar-Shaw

Biocon hits record high on strong Q2 earnings

The stock up 4% to Rs 1,020 after the company posted 52% YoY jump in consolidated net profit at Rs 147 crore in Q2FY17.

Biocon: Scope for long-term gains

There is little doubt about the strength of the company's biosimilar portfolio but upsides are a couple of years away

Biocon appoints Suresh Subramanian head of its branded formulations business

The division is focused on the chronic therapy areas such as diabetes, cancer and autoimmune conditions

Suresh Subramanian to head Biocon's branded formulations biz

Biocon's Branded Formulations (India) business is a biologics-led, speciality pharma business

Biocon hits fresh record high as EMA accepts biosimilar for review

The stock hit a fresh record high of Rs 910, up 5% on the BSE in early morning trade.

European Medical Agency to review Biocon-Mylan's anti cancer biosimilar

This is the partnership's second biosimilar submission that is accepted for review in Europe

Biocon starts 'Ek Prayaas' nationwide awareness on Hepatitis C

As per WHO data, 130-150 mn people globally have chronic Hepatitis C infection, of which 15 mn are in India

Biocon: Positives factored in

The stock hit an all-time high and ended 15 per cent higher at Rs 808.70 on Friday

Biocon to launch insulin glargine in Malaysia in H2 FY 2016-17

Biocon has posted 17% rise in net profit at Rs 147 crore for the first quarter ended June 30

Biocon shares surge 10% post Q1 results

The stock soared 9.9 per cent to touch its one-year high level of Rs 771 at BSE

Biocon up over 5% post Q1 results, EMA review of Biosimilar

The stock surged 7% to Rs 749 after the company reported 35% YoY jump in its consolidated net profit of Rs 167 crore in Q1.

Biocon Q1 profit up 34.45% to Rs 166.6 cr

Biocon and Mylan apply for regulatory approval at EU for biosimilar of anti-cancer drug Pegfilgrastim

Biocon Q1 net up 17% at Rs 147 crore

The company's shares ended at Rs 701.50 apiece on the BSE

Biocon launches insulin Glargine in disposable pens in Japan

The Japanese Glargine market is estimated to be around $144 million, Biocon said in a statement

Biocon gains on launching Insulin Glargine in Japan

The stock was trading higher by 3% at Rs 732 on the National Stock Exchange at 09:27 AM.

Biosimilars: A shot in the arm for Biocon's future prescription

Its huge R&D spending on biosimilars, despite investor apathy, has started to show results

Biocon begins clinical trials for drug to treat rare eye disorder

The drug has been jointly developed with US-based QuarK Pharmaceuticals

Biocon, Quark get DCGI nod for trials of new eye disease drug

The companies also announced the randomisation of the first patient in India in the global Phase II/III study of the new drug candidate